Rockwell Medical, Inc. (RMTI)

Nasdaq: RMTI · Pharmaceutical Preparations · Wixom, MI · filing with the SEC since 1997

Full chart Alerts Compare

Grade4.3

◀ Past 3.4● Present 5.3▶ Future 4.0

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Rockwell Medical, Inc.

Nine metrics read from its own filings, by tense

Headline grade

4.3/10

◀ Past3.425% of the headline

● Present5.335% of the headline

▶ Future4.040% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.4/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.7/10

Has it survived what it has been through?

11 warning events since 2017; the latest 2026-05-08.

weight 22% of this tense · 7th percentile among 497 sector filers · read for itself

From the record

Rockwell Medical, Inc.'s filings since 2017 show 11 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2026-05-08); a warning not to rely on past financial statements (8-K item 4.02, the latest 2018-08-14); an auditor change (8-K item 4.01, 4 times, the latest 2023-04-14); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2022-04-01) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

4.3/10

What has it actually done, year after year?

+2.4% a year over 9 filed years; profitable in 0 of 9.

weight 45% of this tense · 43rd percentile among 323 sector filers · read for its customers

From the record

Rockwell Medical, Inc.'s 9 filed years say what it did: revenue went from $57 million in fiscal 2017 to $69 million in fiscal 2025, up 2.4% a year; it rose in 5 of 8 years; the deepest fall was 32% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

revenue growth over the filed span2.4%bottom 32% of its family
the share of years revenue rosetop 48% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak31.8%top 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

3.8/10

How has it treated the people who own it?

SI estimate 3.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 37th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 37% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Rockwell Medical, Inc.'s shareholder treatment is put at 3.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 37% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.3/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

5.6/10

Is it financially healthy right now?

ROE -14%: lost 14¢ per shareholder dollar. Leverage 35%: owes 35¢ per asset dollar.

weight 45% of this tense · 56th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Rockwell Medical, Inc. lost about 14 cents for every dollar of shareholders' money, and gross profitability: its products earned about 20 cents per dollar of everything the company owns. Leverage: it owed about 35 cents per dollar of assets, and net share issuance: its share count grew 15.8% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 49% of its family
return on equitytop 23% of its family
gross profit against assetsbottom 45% of its family
the share count against the year beforetop 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

5.5/10

How strong is its position in its industry?

top 45% of 315 in its family; net margin -7.7%.

weight 22% of this tense · 55th percentile among 315 sector filers · read for its customers

From the record

Rockwell Medical, Inc.'s standing among 315 graded names in its industry family: revenue of $69 million in fiscal 2025 ranks in the top 40% by size; a net margin of -7.7% ranks in the top 29%; revenue growth of -1.7% a year over the last 3 filed years ranks in the bottom 34% (its annual reports).

What it rests on

revenue against the family$69.3Mtop 40% of its family
net margin-7.7%top 29% of its family
three-year revenue growth-1.7%bottom 34% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

4.5/10

What are the people in charge doing?

bottom 45% of 315 in its family for leadership; chief executive since 2022.

weight 33% of this tense · 45th percentile among 315 sector filers · read for its shareholders

From the record

Rockwell Medical, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Strobeck, Mark (President and CEO, as filed), filing under that title since 2022-07-05, 4.4 years (bottom 44% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 3.7 years (bottom 22%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge3 in three years among 10 peopletop 29% of its family
the median years the people in charge have filed3.7 yearsbottom 22% of its family
the chief executive's years on the record4.4 yearsbottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.0/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

2.4/10

How much room does it have to grow?

bottom 24% of 273 in its family for room to expand.

weight 33% of this tense · 24th percentile among 273 sector filers · read for itself

From the record

Rockwell Medical, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $11 million against debt of $9 million leaves 3.3% of its assets as net cash, bottom 18% of its family; cash from operations less capital spending is -1.7% of revenue (top 30%); a gross margin of 16.9% (bottom 9%); research spending of 0% of revenue (bottom 1%) (its annual report).

What it rests on

cash less debt against assets3.3%bottom 18% of its family
cash from operations less capital spending against revenue-1.7%top 30% of its family
gross margin16.9%bottom 9% of its family
research spending against revenue0.0%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

5.1/10

What could actually drive growth from here?

top 49% of 306 in its family for growth drivers.

weight 45% of this tense · 51st percentile among 306 sector filers · read for its customers

From the record

Rockwell Medical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -1.7% a year over the last three filed years against 2.4% over all 9, slowing (bottom 45% of its family); the newest year grew -31.8% (bottom 24%); capital spending grew 38.1% a year (top 18%) (its annual reports). Rockwell Medical, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-4.1 points a yearbottom 45% of its family
the newest year's revenue growth-31.8%bottom 24% of its family
three-year growth of capital spending38.1%top 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

4.3/10

Did its newest year beat what its own record pointed to?

bottom 43% of 233 in its family for expectations against reality.

weight 22% of this tense · 43rd percentile among 233 sector filers · read for its shareholders

From the record

Rockwell Medical, Inc.'s newest year against its own record: revenue of $69 million in fiscal 2025 came in 42.2% below the $120 million its prior three years' pace pointed to (bottom 22% of its family); net income of $5 million against a prior three-year average of $9 million (top 36%); a net margin of -7.7% against -12.1% before (bottom 42%) (its annual reports).

What it rests on

revenue against the prior three years' pace-42.2%bottom 22% of its family
net income against the prior three years' average+42%top 36% of its family
net margin against its prior average+4.4 pointsbottom 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton RMTI · research, not advice